Glenmark Life Sciences Limited GLS.NS Stock
Glenmark Life Sciences Limited Price Chart
Glenmark Life Sciences Limited GLS.NS Financial and Trading Overview
| Glenmark Life Sciences Limited stock price | 813 INR |
| Previous Close | 601.7 INR |
| Open | 601.7 INR |
| Bid | 590 INR x N/A |
| Ask | 591.25 INR x N/A |
| Day's Range | 586.5 - 604.9 INR |
| 52 Week Range | 370 - 619.65 INR |
| Volume | 174.89K INR |
| Avg. Volume | 237.65K INR |
| Market Cap | 73.3B INR |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 15.663928 |
| EPS (TTM) | 42.39 INR |
| Forward Dividend & Yield | 42 (6.89%) |
| Ex-Dividend Date | March 24, 2023 |
| 1y Target Est | 603 INR |
GLS.NS Valuation Measures
| Enterprise Value | 70.85B INR |
| Trailing P/E | 15.663928 |
| Forward P/E | 12.07848 |
| PEG Ratio (5 yr expected) | 0.96 |
| Price/Sales (ttm) | 3.3917925 |
| Price/Book (mrq) | 3.3880231 |
| Enterprise Value/Revenue | 3.278 |
| Enterprise Value/EBITDA | 11.031 |
Trading Information
Glenmark Life Sciences Limited Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 36.28% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 619.65 INR |
| 52 Week Low | 370 INR |
| 50-Day Moving Average | 510.53 INR |
| 200-Day Moving Average | 432.63 INR |
GLS.NS Share Statistics
| Avg. Volume (3 month) | 237.65K INR |
| Avg. Daily Volume (10-Days) | 225.38K INR |
| Shares Outstanding | 122.53M |
| Float | 21.02M |
| Short Ratio | N/A |
| % Held by Insiders | 82.84% |
| % Held by Institutions | 2.59% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 21 |
| Trailing Annual Dividend Yield | 3.49% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.8266 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 21.60% |
| Operating Margin (ttm) | 27.77% |
| Gross Margin | 53.07% |
| EBITDA Margin | 29.71% |
Management Effectiveness
| Return on Assets (ttm) | 14.50% |
| Return on Equity (ttm) | 22.27% |
Income Statement
| Revenue (ttm) | 21.61B INR |
| Revenue Per Share (ttm) | 176.38 INR |
| Quarterly Revenue Growth (yoy) | 20.89% |
| Gross Profit (ttm) | 11.76B INR |
| EBITDA | 6.42B INR |
| Net Income Avi to Common (ttm) | 4.67B INR |
| Diluted EPS (ttm) | 37.73 |
| Quarterly Earnings Growth (yoy) | 48.00% |
Balance Sheet
| Total Cash (mrq) | 3.09B INR |
| Total Cash Per Share (mrq) | 25.24 INR |
| Total Debt (mrq) | 193.57M INR |
| Total Debt/Equity (mrq) | 0.91 INR |
| Current Ratio (mrq) | 3.668 |
| Book Value Per Share (mrq) | 174.438 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 3.13B INR |
| Levered Free Cash Flow (ttm) | 810.72M INR |
Profile of Glenmark Life Sciences Limited
| Country | India |
| State | N/A |
| City | Mumbai |
| Address | OIA House |
| ZIP | 400099 |
| Phone | 91 22 6829 7979 |
| Website | https://www.glenmarklifesciences.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management. It also provides Atovaquone, Remogliflozin, Teneligliptin, Zonisamide, and Adapalene. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.
Q&A For Glenmark Life Sciences Limited Stock
What is a current GLS.NS stock price?
Glenmark Life Sciences Limited GLS.NS stock price today per share is 813 INR.
How to purchase Glenmark Life Sciences Limited stock?
You can buy GLS.NS shares on the NSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Glenmark Life Sciences Limited?
The stock symbol or ticker of Glenmark Life Sciences Limited is GLS.NS.
Which industry does the Glenmark Life Sciences Limited company belong to?
The Glenmark Life Sciences Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Glenmark Life Sciences Limited have in circulation?
The max supply of Glenmark Life Sciences Limited shares is 122.59M.
What is Glenmark Life Sciences Limited Price to Earnings Ratio (PE Ratio)?
Glenmark Life Sciences Limited PE Ratio is 19.17905200 now.
What was Glenmark Life Sciences Limited earnings per share over the trailing 12 months (TTM)?
Glenmark Life Sciences Limited EPS is 42.39 INR over the trailing 12 months.
Which sector does the Glenmark Life Sciences Limited company belong to?
The Glenmark Life Sciences Limited sector is Healthcare.